Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 12/2008

01-12-2008 | Special Feature

Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis

Authors: P. Szulc, P. D. Delmas

Published in: Osteoporosis International | Issue 12/2008

Login to get access

Abstract

Introduction

The aim was to analyse data on the use of biochemical bone turnover markers (BTM) in postmenopausal osteoporosis.

Methods

We carried out a comparative analysis of the most important papers concerning BTM in postmenopausal osteoporosis that have been published recently.

Results

The BTM levels are influenced by several factors. They are moderately correlated with BMD and subsequent bone loss. Increased levels of bone resorption markers are associated with a higher risk of fracture. Changes in the BTM during the anti-osteoporotic treatment (including combination therapy) reflect the mechanisms of action of the drugs and help to establish their effective doses. Changes in the BTM during the anti-resorptive treatment are correlated with their anti-fracture efficacy.

Conclusion

Biological samples should be obtained in a standardised way. BTM cannot be used for prediction of the accelerated bone loss at the level of the individual. BTM help to detect postmenopausal women who are at high risk of fracture; however, adequate practical guidelines are lacking. BTM measurements taken during the anti-resorptive therapy help to identify non-compliers. They may improve adherence to the anti-resorptive therapy and the fall in the BTM levels that exceeds the predefined threshold improves patients’ persistence with the treatment. There are no guidelines concerning the use of BTM in monitoring anti-osteoporotic therapy in postmenopausal women.
Literature
1.
Dempster DW (2006) Anatomy and functions of the adult skeleton. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, DC, pp 7–11
2.
Garnero P, Delmas PD (2001) Biochemical markers of bone turnover in osteoporosis. In: Marcus M, Feldman D, Kelsey J (eds) Osteoporosis, vol 2. Academic Press, New York, pp 459–477
3.
Delmas PD, Demiaux B, Malaval L, Chapuy MC, Edouard C, Meunier PJ (1986) Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia comparison with bone histomorphometry. J Clin Invest 77:985–991PubMedCrossRef
4.
Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC (1996) Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 7:506–512PubMed
5.
Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J (1993) Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 8:127–132PubMed
6.
Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL (1988) Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 67:741–748PubMedCrossRef
7.
Charles P, Poser JW, Mosekilde L, Jense FT (1985) Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J Clin Invest 76:2254–2258PubMedCrossRef
8.
Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK (2006) Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52:499–509PubMed
9.
Roux JP, Arlot ME, Gineyts E, Meunier PJ, Delmas PD (1995) Automatic-interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline. Bone 17:153–156PubMedCrossRef
10.
Eastell R, Colwell A, Hampton L, Reeve J (1997) Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res 12:59–65PubMedCrossRef
11.
Denk E, Hillegonds D, Hurrell RF et al (2007) Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. J Bone Miner Res 22:1518–1525PubMedCrossRef
12.
Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57–61PubMedCrossRef
13.
Eastell R, Simmons PS, Colwell A et al (1992) Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing. Clin Sci 83:375–382PubMed
14.
Wichers M, Schmidt E, Bidlingmaier F, Klingmüller D (1999) Diurnal rhythm of crosslaps in human serum. Clin Chem 45:1858–1860PubMed
15.
Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S (1998) Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102–106PubMedCrossRef
16.
Aoshima H, Kushida K, Takahashi M et al (1998) Circadian variation of urinary type I collagen crosslinked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks. Bone 22:73–78PubMedCrossRef
17.
Bollen AM, Martin MD, Leroux BG, Eyre DR (1995) Circadian variation in urinary excretion of bone collagen cross-links. J Bone Miner Res 10:1885–1890PubMed
18.
Schlemmer A, Hassager C (1999) Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 140:332–337PubMedCrossRef
19.
Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886–890PubMedCrossRef
20.
Henriksen DB, Alexandersen P, Bjarnason NH et al (2003) Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18:2180–2189PubMedCrossRef
21.
Brooke-Wavell K, Jones PRM, Hardman AE, Tsuritani I, Yamada Y (2001) Commencing, continuing and stopping brisk walking: effects on bone mineral density, quantitative ultrasound of bone and markers of bone metabolism in postmenopausal women. Osteoporos Int 12:581–587PubMedCrossRef
22.
Hla MM, Davis JW, Ross PD, Yates AJ, Wasnich RD (2001) The relation between lifestyle factors and biochemical markers of bone turnover among early postmenopausal women. Calcif Tissue Int 68:291–296PubMedCrossRef
23.
Suleiman S, Nelson M, Li F, Buxton-Thomas M, Moniz C (1997) Effect of calcium intake and physical activity level on bone mass and turnover in healthy, white, postmenopausal women. Am J Clin Nutr 66:937–943PubMed
24.
Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP (1992) Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 74:481–486PubMedCrossRef
25.
Alvarez L, Guanabens N, Peris P et al (1995) Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 10:458–463PubMed
26.
Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD (1998) Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 41:354–360PubMedCrossRef
27.
Pantazi H, Papapetrou PD (2000) Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 85:1099–1106PubMedCrossRef
28.
Siddiqi A, Burrin JM, Noonan K et al (1997) A longitudinal study of markers of bone turnover in Graves’ disease and their value in predicting bone mineral density. J Clin Endocrinol Metab 82:753–759PubMedCrossRef
29.
Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650–5655PubMedCrossRef
30.
Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol 154:109–118PubMedCrossRef
31.
Chiodini I, Carnevale V, Torlontano M et al (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing’s syndrome. J Clin Endocrinol Metab 83:1863–1867PubMedCrossRef
32.
Alaxandrakis MG, Passam FH, Malliaraki N, Katachanakis C, Kyriakou DS, Margioris N (2002) Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 325:51–57CrossRef
33.
Corso A, Arcaini L, Mangiacavalli S et al (2001) Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 86:394–398PubMed
34.
Colao A, di Somma C, Pivonello R et al (1999) Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 84:1919–1924PubMedCrossRef
35.
Mizunashi K, Furukawa Y, Miura R, Yumita S, Sohn HE, Yoshinaga K (1988) Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism. J Clin Invest 82:861–865PubMedCrossRef
36.
Engler H, Oettli RE, Riesen WF (1999) Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: a cross-sectional study. Clin Chim Acta 289:159–172PubMedCrossRef
37.
White HD, Ahmad AM, Durham BH et al (2006) Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab 91:913–919PubMedCrossRef
38.
Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P (2006) Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a cross-sectional and longitudinal evaluation. Br J Cancer 95:506–514PubMedCrossRef
39.
Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB (2006) The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32–38PubMedCrossRef
40.
Cloos PA, Lyubimova N, Solberg H et al (2004) An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 50:279–289PubMed
41.
Costa L, Demers LM, Gouveia-Oliveira A et al (2002) Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20:850–856PubMedCrossRef
42.
Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925–4935PubMedCrossRef
43.
Chen JS, Cameron ID, Cumming RG et al (2006) Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res 21:324–331PubMedCrossRef
44.
Nilsson K, Gustafson L, Isaksson A, Hultberg B (2005) Plasma homocysteine and markers of bone metabolism in psychogeriatric patients. Scand J Clin Lab Invest 65:671–680PubMedCrossRef
45.
Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K (2005) Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord 20:1598–1603PubMedCrossRef
46.
Sato Y, Asoh T, Oizumi K (1998) High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer’s disease. Bone 23:555–557PubMedCrossRef
47.
Sato Y, Oizumi K, Kuno H, Kaji M (1999) Effect of immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly stroke patients. Bone 24:271–275PubMedCrossRef
48.
Sato Y, Kuno H, Kaji M, Ohshima Y, Asoh T, Oizumi K (1998) Increased bone resorption during the first year after stroke. Stroke 29:1373–1377PubMed
49.
Iwamoto J, Takeda T, Ichimura S (2001) Relationships between physical activity and metacarpal cortical bone mass and bone resorption in hemiplegic patients. J Orthop Sci 6:227–233PubMedCrossRef
50.
Ivaska KK, Gerdhem P, Akesson K, Garnero P, Obrant KJ (2007) Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 22:1155–1164PubMedCrossRef
51.
Stoffel K, Engler H, Kuster M, Riesen W (2007) Changes in biochemical markers after lower limb fractures. Clin Chem 53:131–134PubMedCrossRef
52.
Obrant KJ, Ivaska KK, Gerdhem P, Alantalo SL, Pettersson K, Väänänen HK (2005) Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone 36:786–792PubMedCrossRef
53.
Lems WF, van Veen GJM, Gerrits MI et al (1998) Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br J Rheumat 37:27–33CrossRef
54.
Ton FJ, Gunawardene SC, Lee H, Neer RM (2005) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20:464–470PubMedCrossRef
55.
Richy F, Bousquet J, Ehrlich GE et al (2003) Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 14:179–190PubMed
56.
Scanlon PD, Connett JE, Wise RA et al (2004) Loss of bone density with inhaled triamcinolone in Lung Health Study. Am J Resp Crit Care Med 170:1302–1309PubMedCrossRef
57.
Fardon TC, Lee DKC, Haggart K, McFarlane LC, Lipworth BJ (2004) Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Resp Crit Care Med 170:960–966PubMedCrossRef
58.
Martin RJ, Szefler SJ, Chinchilli VM et al (2002) Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Resp Crit Care Med 165:1377–1383PubMedCrossRef
59.
Egan JJ, Maden C, Kalra S, Adams JE, Eastell R, Woodcock AA (1999) A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur Resp J 13:1267–1275
60.
Malerba M, Bossoni S, Radaeli A et al (2005) Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest 127:515–521PubMedCrossRef
61.
Fujita K, Kasayama S, Hashimoto J et al (2001) Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women. J Bone Miner Res 16:782–787PubMedCrossRef
62.
Hall GM, Spector TD, Delmas PD (1995) Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 38:902–906PubMedCrossRef
63.
Pearce G, Ryan PFJ, Delmas PD, Tabensky DA, Seeman E (1998) The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheum 37:292–299CrossRef
64.
Brufsky A, Harker WG, Beck JT et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829–836PubMedCrossRef
65.
Gonnelli S, Cadirni A, Caffarelli C et al (2007) Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40:205–210PubMedCrossRef
66.
Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41:346–352PubMedCrossRef
67.
Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res 21:1215–1223PubMedCrossRef
68.
Fitzpatrick LA (2004) Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5:S3–S15PubMedCrossRef
69.
70.
Pack A, Shane E, McMahon D, Randall A, Morell M (2007) Antiepileptic drugs affect bone loss via reproductive hormones. J Bone Miner Res 22 [Suppl 1]:S467, Abstract W415
71.
Mintzer S, Boppana P, Toguri J, DeSantis A (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine and oxcarbazepine. Epilepsia 47:510–515PubMedCrossRef
72.
Pack AM, Morrell MJ, Marcus R et al (2005) Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 57:252–257PubMedCrossRef
73.
Verrotti A, Greco R, Morgese G, Chiarelli F (2000) Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47:385–388PubMedCrossRef
74.
Lau KHW, Nakade O, Barr B, Taylor AK, Houchin K, Baylink DJ (1995) Phenytoin increases markers of osteogenesis for human species in vitro and in vivo. J Clin Endocrinol Metab 80:2347–2353PubMedCrossRef
75.
Kim SH, Lee JW, Choi KG, Chung HW, Lee HW (2007) A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 10:291–295PubMedCrossRef
76.
Sato Y, Kondo I, Ishida S et al (2001) Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57:445–449PubMed
77.
Toh S, Hernandez-Diaz S (2007) Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 16(6):627–640PubMedCrossRef
78.
Bone HG, Kiel DP, Lindsay RS et al (2007) Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 92:4671–4677PubMedCrossRef
79.
Berthold HK, Unverdorben S, Zittermann A et al (2004) Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women. Osteoporos Int 15:459–467PubMedCrossRef
80.
Braatvedt GD, Bagg W, Gamble G, Davidson J, Reid IR (2004) The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 35:766–770PubMedCrossRef
81.
Rejnmark L, Buus NH, Vestergaard P et al (2004) Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 19:737–744PubMedCrossRef
82.
Rosenson RS, Tangney CC, Langman CB, Parker TS, Mevine DM, Gordon BR (2005) Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int 16:1272–1276PubMedCrossRef
83.
Montagnani A, Gonnelli S, Cepollaro C et al (2003) Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 32:427–433PubMedCrossRef
84.
Mostaza JM, de la Piedra C, Curiel MD, Pena R, Lahoz C (2001) Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women. Clin Chim Acta 308:133–137PubMedCrossRef
85.
Ho-Ming Chan M, Wing-Lai M, Wai-Kwun Chiu R, Chow CC, Hiu-Shuen I, Wai-Kei Lam C (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 86:4556–4559CrossRef
86.
87.
Grey A, Bolland M, Gamble G et al (2007) The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305–1310PubMedCrossRef
88.
Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Tutuncu NB, Demirag NG (2007) Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92:3523–3530PubMedCrossRef
89.
Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T (2003) Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21:166–171PubMedCrossRef
90.
Okazaki R, Miura M, Toriumi M et al (1999) Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795–801PubMedCrossRef
91.
92.
Knapen MHJ, Hellemons-Boode BSP, Langenberg-Ledeboer M et al (2000) Effect of oral anticoagulant treatment on markers for calcium and bone metabolism. Haemostasis 30:290–297PubMedCrossRef
93.
Obrant KJ, Käkönen SM, Astermark J et al (1999) The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects. J Bone Miner Res 14:555–560PubMedCrossRef
94.
Menon RK, Gill DS, Thomas M, Kernoff PBA, Dandona P (1987) Impaired carboxylation of osteocalcin in warfarin-treated patients. J Clin Endocrinol Metab 64:59–61PubMedCrossRef
95.
Pietschmann P, Woloszczuk W, Panzer S, Kyrle P, Smolen J (1988) Decreased serum osteocalcin levels in phenprocoumon-treated patients. J Clin Endocrinol Metab 66:1071–1074PubMed
96.
Chapuy MC, Schott AM, Garnero P, Hans D, Delmas PD, Meunier PJ (1996) Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. J Clin Endocrinol Metab 81:1129–1133PubMedCrossRef
97.
Theiler R, Stähelin HB, Kräzlin M, Tyndall A, Bischoff HA (1999) High bone turnover in the elderly. Arch Phys Med Rehabil 80:485–489PubMedCrossRef
98.
Theiler R, Stähelin HB, Kräzlin M et al (2000) Influence of physical mobility and season on 25-hydroxyvitamin D-parathyroid hormone interaction and bone remodelling in the elderly. Eur J Endocrinol 143:673–679PubMedCrossRef
99.
Rapuri PB, Kinaymu HK, Gallagher JC, Haynatzka V (2002) Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women. J Clin Endocrinol Metab 87:2024–2032PubMedCrossRef
100.
Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11 [Suppl 6]:30–44CrossRef
101.
Smith SM, Dillon EL, DeKerlagand DE, Davis-Street JE (2004) Variablity of collagen crosslinks: impact of sample collection period. Calcif Tissue Int 74:336–341PubMedCrossRef
102.
Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337–349PubMed
103.
Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD (2003) Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 18:1789–1794PubMedCrossRef
104.
Chaki O, Yoshikata I, Kikuchi R et al (2000) The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res 15:1537–1544PubMedCrossRef
105.
Löfman O, Magnusson P, Toss G, Larsson L (2005) Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study. Clin Chim Acta 356:67–75PubMedCrossRef
106.
Schneider DL, Barrett-Connor EL (1997) Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 157:1241–1245PubMedCrossRef
107.
Sherman SS, Tobin JD, Hollis BW, Gundberg CM, Roy TA, Plato CC (1992) Biochemical parameters associated with low bone density in healthy men and women. J Bone Miner Res 7:1123–1130PubMed
108.
Stepan JJ (2000) Prediction of bone loss in premenopausal women. Osteoporos Int 11 [Suppl 6]:S45–S54PubMedCrossRef
109.
Iki M, Morita A, Ikeda Y et al (2006) Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women—the Japanese Population-based Osteoporosis (JPOS) cohort study. Osteoporosis Int 17:1086–1095CrossRef
110.
Chapurlat RD, Garnero P, Sprnay-Rendu E, Arlot ME, Claustrat B, Delmas PD (2000) Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int 11:493–498PubMedCrossRef
111.
Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD (1999) Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 14:1614–1621PubMedCrossRef
112.
Rogers A, Hannon RA, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15:1398–1404PubMedCrossRef
113.
Cheng S, Suominen H, Väänänen K, Käkönen SM, Pettersson K, Heikkinen E (2002) Serum osteocalcin in relation to calcaneal bone mineral density in elderly men and women: a 5-year follow-up. J Bone Miner Metab 20:49–56PubMedCrossRef
114.
Melton LJ III, Atkinson EJ, O’Connor MK, O’Fallon W, Riggs BL (2000) Determinants of bone loss from the femoral neck in women of different ages. J Bone Miner Res 15:24–31PubMedCrossRef
115.
Yoshimura N, Hashimoto T, Sakata K, Morioka S, Kasamatsu T, Copper C (1999) Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study. Osteoporos Int 65:198–202
116.
Dennison E, Eastell R, Fall CHD, Kellingray S, Wood PJ, Cooper C (1999) Determinants of bone loss in elderly men and women: a prospective population-based study. Osteoporos Int 10:384–391PubMedCrossRef
117.
Bauer DC, Sklarin PM, Stone KL et al (1999) Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 14:1404–1410PubMedCrossRef
118.
Slemenda C, Longcope C, Peacock M, Hui S, Johston CC (1996) Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest 97:14–21PubMedCrossRef
119.
Keen RW, Nguyen T, Sobnack R, Perry LA, Thompson PW, Spector TD (1996) Can biochemical markers predict bone loss at the hip and spine ? A 4-year prospective study of 141 early postmenopausal women. Osteoporos Int 6:399–406PubMedCrossRef
120.
Cummings SR, Palermo L, Browner W (2000) Monitoring osteoporosis therapy with bone densitometry. Misleading changes and regression to the mean. JAMA 283:1318–1321PubMedCrossRef
121.
Christiansen C, Riis BJ, Rodbro P (1987) Prediction of rapid bone loss in postmenopausal women. Lancet I:1105–1108CrossRef
122.
Ross PD, Knowlton W (1998) Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 13:297–302PubMedCrossRef
123.
Akesson K, Ljunghall S, Jonsson B et al (1995) Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 10:1823–1829PubMed
124.
Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536PubMedCrossRef
125.
Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 11:76–82PubMedCrossRef
126.
Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P (2000) Predictors of fractures in elderly women. Osteoporos Int 11:134–140PubMedCrossRef
127.
Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD (2002) Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 17:826–833PubMedCrossRef
128.
Bruyère O, Collette J, Delmas P et al (2003) Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal women. Maturitas 44:259–265PubMedCrossRef
129.
Melton LJ III, Crowson CS, O’Fallon WM, Wahner HW, Riggs BL (2003) Relative contribution of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 18:312–318PubMedCrossRef
130.
Gerdhem P, Ivaska KK, Alatalo SL et al (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386–393PubMedCrossRef
131.
Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813–1819PubMedCrossRef
132.
Ivaska KK, Gerdhem P, Akesson K, Obrant KJ (2007) Bone turnover markers and prediction of fracture: nine-year follow-up study of 1040 elderly women. J Bone Miner Res 22 [Suppl 1]:S21, Abstract 1073
133.
Garnero P, Hausher E, Chapuy MC et al (1996) Markers of bone resorption predict hip fracture in elderly women: the Epidos prospective study. J Bone Miner Res 11:1531–1538PubMed
134.
Chapurlat RD, Garnero P, Bréart G, Meunier PJ, Delmas PD (2000) Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 27:283–286PubMedCrossRef
135.
Chen JS, Seibel MJ, Zochling J et al (2006) Calcaneal ultrasound but not bone turnover predicts fractures in vitamin D deficient frail elderly at high risk of falls. Calcif Tissue Int 79:37–42PubMedCrossRef
136.
Garnero P, Dargent-Molina P, Hans D et al (1998) Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8:563–569PubMedCrossRef
137.
Weel AEAM, Seibel MJ, Hofman A, Leeuwen JPTM, Pols HAP (1999) Which fractures are associated with high bone resorption in elderly women: the Rotterdam study. J Bone Miner Res 14 [Suppl 1]:S160, Abstract 1110
138.
Dobnig H, Piswanger-Sölkner JC, Obermayer-Pietsch B et al (2007) Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab 92:1678–1686PubMedCrossRef
139.
Johnell O, Oden A, de Laet C, Garnero P, Delmas PD, Kanis JA (2002) Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 13:523–526PubMedCrossRef
140.
Robbins JA, Schott AM, Garnero P, Delmas PD, Hans D, Meunier PJ (2005) Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int 16:149–154PubMedCrossRef
141.
Delmas PD, Licata AA, Reginster JY et al (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39:237–243PubMedCrossRef
142.
Bauer DC, Garnero P, Hochberg MC et al DM (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299PubMedCrossRef
143.
Schousboe JT, Bauer DC, Nyman JA, Kane RL, Melton LJ, Ensrud KE (2007) Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 18:201–210PubMedCrossRef
144.
Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11 [Suppl 6]:S55–S65PubMedCrossRef
145.
Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736–746PubMedCrossRef
146.
Szulc P, Seeman E, Dubeouf F, Sornay-Rendu E, Delmas PD (2006) Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res 21:1856–1863PubMedCrossRef
147.
Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261PubMedCrossRef
148.
Dempster DW (2000) The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res 15:20–23PubMedCrossRef
149.
Follet H, Boivin G, Rumelhart C, Meunier PJ (2004) The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone 34:783–789PubMedCrossRef
150.
Viguet-Carin S, Roux JP, Arlot ME et al (2006) Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39:1073–1079CrossRef
151.
Oxlund H, Barckman M, Ortoft G, Andreassen TT (1995) Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 17 [Suppl 4]:365S–371SPubMed
152.
Banse X, Sims TJ, Bailey AJ (2002) Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermollecular cross-links. J Bone Miner Res 17:1621–1628PubMedCrossRef
153.
Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD (1995) Different effects of bisphosphonate and estrogen therapy on free and peptide-bound cross-links excretion. J Bone Miner Res 10:641–649PubMedCrossRef
154.
Colwell A, Eastell R (1996) The renal clearance of free and conjugated pyridinium cross-links of collagen. J Bone Miner Res 11:1976–1980PubMed
155.
Bonnick S, Saag KG, Kiel DP et al (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endcrinol Metab 91:2631–1637CrossRef
156.
157.
Liberman UM, Weiss SR, Broll J (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333:1437–1443PubMedCrossRef
158.
Harris ST, Watts NB, Genant HK (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344–1352PubMedCrossRef
159.
160.
Kim MK, Kim HD, Park JH et al (2006) An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-flouro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats. J Pharmacol Exp Ther 318:555–562PubMedCrossRef
161.
McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMedCrossRef
162.
Papanastasiou P, Ortmann CE, Olson M, Vigneron A, Trechsel U (2006) Effect of three month treatment with the cathepsin K inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women. Evidence for uncoupling of bone resorption and bone formation. J Bone Miner Res 21 [Suppl 1]:S59, Abstract 1223
163.
Delmas PD, Bjarnason NH, Mitlak BH (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647PubMedCrossRef
164.
Ravn P, Clemmesen B, Riis BJ, Christiansen C (1996) The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19:527–533PubMedCrossRef
165.
Thiébaud D, Burckhardt P, Kriegbaum H et al (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298–307PubMedCrossRef
166.
Christiansen C, Tanko LB, Warming L et al (2003) Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int 14:609–613PubMedCrossRef
167.
Greenspan SL, Bone HG, Ettinger MP et al (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326–339PubMed
168.
Chen P, Satterwhite JH, Licata AA et al (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970PubMedCrossRef
169.
Dobnig H, Sipos A, Jiang Y et al (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970–3977PubMedCrossRef
170.
Hodsman AB, Hanley DA, Ettinger MP et al (2003) Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mienral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220PubMedCrossRef
171.
Lindsay R, Nieves J, Formica C et al (1997) Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555PubMedCrossRef
172.
Eastell R, McCloskey EV, Glover S et al (2007) Rapid and robust biochemical response to teriparatide therapy for osteoporosis. J Bone Miner Res 22 [Suppl 1]:S322, Abstract T366
173.
Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434–1446PubMedCrossRef
174.
Aubin JE, Lian JB, Stein GS (2006) In: Favus M (ed) Bone formation: maturation and functional activities of osteoblast lineage cells. Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. American Society for Bone and Mineral Research, Washington, DC, pp 20–29
175.
Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2007) Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007 22:495–502PubMedCrossRef
176.
Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRef
177.
Delmas PD, Pornel B, Felsenberg D et al (1999) A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women. Bone 24:517–523PubMedCrossRef
178.
McClung M, Clemmensen B, Daifotis A (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med 128:253–261PubMed
179.
Harris ST, Gertz BJ, Genant HK et al (1993) The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J Clin Endocrinol Metab 76:1399–1406PubMedCrossRef
180.
Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654–661PubMedCrossRef
181.
McClung M, Wasnich R, Recker R et al (2004) Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 19:11–18PubMedCrossRef
182.
Tanko LB, Felsenberg D, Czerwinski E et al (2003) Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 254:159–167PubMedCrossRef
183.
Reid IR, Brown JP, Burckhardt P (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661PubMedCrossRef
184.
185.
Prestwood KM, Kenny AM, Unson C, Kulldorff M (2000) The effect of low dose micronized 17β-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 85:4462–4469PubMedCrossRef
186.
Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M (2003) Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women. A randomized controlled trial. JAMA 290:1042–1048PubMedCrossRef
187.
Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668–2676PubMedCrossRef
188.
Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599–604PubMedCrossRef
189.
Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19:330–337PubMedCrossRef
190.
Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMedCrossRef
191.
Chapurlat RD, Palermo L, Ramsay P, Cummings SR (2005) Risk of fracture among women who lose bone density during treatment with alendronate. The fracture intervention trial. Osteoporos Int 16:842–848PubMedCrossRef
192.
Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRef
193.
Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056PubMedCrossRef
194.
Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD (2007) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 22:1656–1660PubMedCrossRef
195.
Reginster JY, Sarkar S, Zegels B et al (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344–351PubMedCrossRef
196.
Bjarnasson NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922–930CrossRef
197.
Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM (1998) Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1–34). A randomized control trial. JAMA 280:1067–1073PubMedCrossRef
198.
Bauer DC, Garnero P, Bilezikian JP et al (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370–1375PubMedCrossRef
199.
Wasnich RD, Bagger YZ, Hosking DJ et al (2004) Changes in bone density and turnover after alendronate or estrogen withdrawal. Maturitas 11:622–630
200.
Sornay-Rendu E, Garnero P, Munoz F, Duboeuf F, Delmas PD (2003) Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone 33:159–166PubMedCrossRef
201.
Greenspan SL, Emkey RD, Bone HG (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875–883PubMed
202.
Gallagher JC, Rapuri PB, Haynatzki G, Detter JR (2002) Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 87:4914–4923PubMedCrossRef
203.
Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black DM, Cummings SR (1995) Estrogen replacement therapy and fractures in older women. Study of osteoporotic fractures research group. Ann Intern Med 122:9–16PubMed
204.
Raisz L, Smith JA, Trahiotis M et al (2000) Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 11:615–620PubMedCrossRef
205.
Ravn P, Christensen JO, Baumann M, Clemmensen B (1998) Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 22:559–564PubMedCrossRef
206.
Watts NB, Chines A, Olszynski WP et al (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372PubMedCrossRef
207.
Bone HG, Hosking D, Devolelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRef
208.
Tonino RP, Meunier PJ, Emkey R et al (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85:3109–3115PubMedCrossRef
209.
Ravn P, Bidstrup M, Wasnich RD et al (1999) Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 131:935–942PubMed
210.
Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef
211.
Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C (2003) Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33:301–307PubMedCrossRef
212.
Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the fracture intervention trial long-term extension. J Bone Miner Res 19:1259–1269PubMedCrossRef
213.
Black DM, Bilezikian JP, Ensrud KE et al (2005) One year alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565PubMedCrossRef
214.
Black DM, Greenspan SL, Ensrud KE et al (2003) The effects of parathyroid hormone and alendronate alone or in comination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215PubMedCrossRef
215.
Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751PubMedCrossRef
216.
Delmas PD, Watts N, Miller P, Cahall D, Bilezikian J, Lindsay R (2007) Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: the OPTAMISE study. J Bone Miner Res 22 [Suppl 1]:S27, Abstract 1092
217.
Rittmaster RS, Bolognese M, Ettinger MP et al (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134PubMedCrossRef
218.
Black DM, Bauer DC, Rosen CJ, Greenspan SL, Bilezikian JP (2007) Prediction of 24 month change in BMD on PTH followed by alendronate: the PaTH study. J Bone Miner Res 22 [Suppl 1]:S26, Abstract 1090
219.
Eviö S, Tiitinen A, Laitinen K, Ylikorkala O, Välimäki MJ (2004) Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 89:626–631PubMedCrossRef
220.
Lindsay R, Cosman F, Lobo RA et al (1999) Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84:3076–3081PubMedCrossRef
221.
Harris ST, Eriksen EF, Davidson M et al (2001) Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86:1890–1897PubMedCrossRef
222.
Warming L, Ravn P, Christiansen C (2005) Levonorgestrel and 17β-estradiol given transdermally for the prevention of postmenopausal osteoporosis. Maturitas 50:78–85PubMedCrossRef
223.
Liu JH, Muse KN (2005) The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 192:1316–1324PubMedCrossRef
224.
Tobias JH, Clarke S, Mitchell K, Robins S, Amer H, Fraser WD (2001) Analysis of the contribution of dydrogesterone to bone turnover changes in postmenopausal women commencing hormone replacement therapy. J Clin Endocrinol Metab 86:1194–1198PubMedCrossRef
225.
Raisz LG, Wiita B, Artis A et al (1996) Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 81:37–43PubMedCrossRef
226.
Committee for Medicinal Products for Human Use—Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. European Medicinal Agency CPMP/EWP/552/95 Rev. 2
227.
Rizzoli R, the Alendronate Once-weekly Study Group (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988–1996PubMedCrossRef
228.
Watts NB, Lindsay R, Li Z, Kasibhatla C, Brown J (2003) Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 14:437–441PubMedCrossRef
229.
Brown JP, Kendler DL, McClung MR et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103–111PubMedCrossRef
230.
Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal women. J Bone Miner Res 19:1241–1249CrossRef
231.
Delmas PD, Recker RR, Chesnut CH III et al (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798PubMedCrossRef
232.
Miller PD, McClung MR, Macovei L et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315–1322PubMedCrossRef
233.
Papapoulos S, Schimmer R (2007) Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66:853–838PubMedCrossRef
234.
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef
235.
Eastell R, Garnero P, Vrijens B et al (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:408, Abstract P-297
236.
Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with anti-resorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef
237.
Delmas PD, Vrijens B, Eastell R et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRef
238.
Delmas PD (2000) Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11 [Suppl 6]:S66–S76PubMedCrossRef
Metadata
Title
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis
Authors
P. Szulc
P. D. Delmas
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 12/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0660-9

Other articles of this Issue 12/2008

Osteoporosis International 12/2008 Go to the issue

Letter

Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert

Letter

Calculating clinically relevant drug doses to use in animal studies

Editorial

Opportunities in population-specific osteoporosis research and management

Original Article

Genetic influences on bone loss in the San Antonio Family Osteoporosis study

Original Article

Incidence of fractures compared to cardiovascular disease and breast cancer: the Women’s Health Initiative Observational Study

Letter

Effective doses for strontium ranelate